Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imaging Sub-Study of Phase III Trial of Odanacatib to Reduce Fracture Risk in Postmenopausal Osteoporosis
2008-004578-42Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postmenopausal osteoporosis comparing Odanacatib arm with Placebo arm (2 arms). Primary endpoint: Volumetric trabecular bone mineral density. Started Sep 2008; status: completed.
02
Drugs
odanacatib
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on 2008-004578-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004578-42.